Cervical pessary versus vaginal progesterone in women with a multiple pregnancy and a short cervix: A randomised controlled trial
PLOS Medicine · 2025
DOI: 10.1371/journal.pmed.1004586 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, 2025. Verfasst von Charlotte E van Dijk und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Progesterone, Pessaries, Premature Birth, Cervix Uteri. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Stop te Vroeg Bevallen.
Abstract (Originalsprache)
Background
In absence of direct comparisons, consensus on the preferred preventive treatment for multiple pregnancies with a short cervix is lacking. Therefore, we compared the effectiveness of a cervical pessary and vaginal progesterone in the prevention of adverse perinatal outcomes and preterm birth (PTB) in women with a multiple pregnancy, no prior spontaneous PTB (sPTB) before 34 weeks’ gestation, and an asymptomatic mid-trimester shortened cervix below 38 mm. Methods and findings This open-label, superiority, multi-centre randomised controlled trial was conducted in 20 hospitals in the Netherlands. Women with a healthy multiple pregnancy and an asymptomatic cervical length (CL) below 38 mm between 16 and 22 weeks’ gestation were eligible, with a target sample size of 332. Following an interim analysis, the study was halted for futility. A total of 276 multiples, including seven triplet pregnancies, were randomised 1:1 to receive either an Arabin cervical pessary ( N = 138) or vaginal progesterone 200 mg daily ( N = 138) until 36 weeks’ gestation or earlier if indicated. The primary outcome was a composite adverse perinatal outcome, with secondary outcomes including rates of (s)PTB before 24, 28, 32, 34, and 37 weeks. Predefined subgroup analyses were conducted based on CL, parity, chorionicity, and number of foetuses. Among 531 neonates (pessary N = 269, progesterone N = 262), the composite adverse perinatal outcome occurred in 19.7% of neonates in the pessary group versus 13.7% in the progesterone group (crude RR 1.43; 95% CI [0.85,2.4], p = 0.18). The rates of (s)PTB were not significantly different between groups. In the subgroup with a CL of ≤25 mm, no significant difference in the composite perinatal outcome was found (41.1% versus 34.7%, RR 1.18; 95% CI [0.60,2.33], interaction p = 0.63). However, among nulliparous women, the composite outcome was more frequent in the pessary group compared to progesterone (30.0% versus 15.9%, RR 1.88; 95% CI [1.03,3.43], interaction p = 0.93). The study’s main limitations include the inability to blind interventions, potentially introducing bias, and low self-reported medication compliance in the progesterone group, which may have led to overestimated adherence and underestimated progesterone’s preventive potential in the per-protocol analysis.
Conclusion
In women with multiple pregnancies and a midtrimester short cervix below 38 mm, we found no superiority of a cervical pessary compared to vaginal progesterone the prevention of perinatal complications. While progesterone may have a modest effect, future studies should focus on other interventions in multiple pregnancies such as a cerclage, both ultrasound- and physical examination-indicated.
Trial registration
This trial was registered at the International Clinical Trial Registry Platform (ICTRP, EUCTR2013-002884-24-NL, https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-002884-24-NL ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands.
- Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
- Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Radboud University, Nijmegen, the Netherlands.
- Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
- Department of Obstetrics and Gynaecology, Flevoziekenhuis, Almere, the Netherlands.
ORCID-Profile: Charlotte E van Dijk, Annabelle L van Gils, Marijke C van der Weide, Karlijn C Vollebregt, Sanne J Gordijn, Martijn A Oudijk, Ben W J Mol, Eva Pajkrt
Förderung
- Stichting Stop te Vroeg Bevallen
Zitieren
APA
van Dijk, C. E., van Gils, A. L., van Zijl, M. D., Koullali, B., van der Weide, M. C., van den Akker, E. S., Hermsen, B. J., van Drongelen, J., de Boer, M. A., van Baal, W. M., Vollebregt, K. C., van der Made, F. W., Gordijn, S. J., Sueters, M., Wijnberger, L. D. E., Oudijk, M. A., Mol, B. W. J., Kazemier, B. M., Pajkrt, E., & Quadruple P Research Group (2025). Cervical pessary versus vaginal progesterone in women with a multiple pregnancy and a short cervix: A randomised controlled trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004586
Vancouver
van Dijk CE, van Gils AL, van Zijl MD, Koullali B, van der Weide MC, van den Akker ES, et al. Cervical pessary versus vaginal progesterone in women with a multiple pregnancy and a short cervix: A randomised controlled trial. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004586
BibTeX
@article{vanDijk2025,
author = {van Dijk, Charlotte E and van Gils, Annabelle L and van Zijl, Maud D and Koullali, Bouchra and van der Weide, Marijke C and van den Akker, Eline S and Hermsen, Brenda J and van Drongelen, Joris and de Boer, Marjon A and van Baal, Wilhelmina M and Vollebregt, Karlijn C and van der Made, Flip W and Gordijn, Sanne J and Sueters, Marieke and Wijnberger, Lia D E and Oudijk, Martijn A and Mol, Ben W J and Kazemier, Brenda M and Pajkrt, Eva and Quadruple P Research Group, Quadruple P Research Group},
title = {Cervical pessary versus vaginal progesterone in women with a multiple pregnancy and a short cervix: A randomised controlled trial},
journal = {PLOS Medicine},
year = {2025},
doi = {10.1371/journal.pmed.1004586}
}
EUVIMED